obesity and glp 1 Frontiers GLP-1 Therapy Part 1: Setting

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field

Butyrate is a short chain fatty acid which is a fermentation by-product of dietary fiber in the gut microbiome [3]

No compounding

Andrew Stokes received a grant from the Robert Wood Johnson Foundation analyze the real-word effects of this new class of appetite-suppressing therapies, as well as inequities in access to these medications.

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.